Ocu410

Phase 3

OOcugen

Ocu410 is one of 32 therapeutic programs targeting Age-Related Macular Degeneration. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Age-Related Macular DegenerationPhase 3

Recruiting

Competition

Competitive Landscape

39 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Eylea

Regeneron

Approved

37 2

Bayer Aspirin

Tecfidera

Plavix

Zometa

Visudyne

BBausch Health Americas, Inc.

Approved

1 7

Bendopa

MMerz North America, Inc.

Lodosyn

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—10

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 3Recruiting

Age-Related Macular Degeneration

NCT07770828

Clinical

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

A Phase 3 Registrational Study To Assess The Efficacy, Safety, And Tolerability Of OCU410 For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration

Recruiting·OOcugen·Phase 3·NCT07770828·237 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ocu410. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ocu410. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ocugen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: OOcugen

Ocu410

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

References

Drug Info

Quick Facts

Related News